SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 126.37 |
| Enterprise Value ($M) | 70.73 |
| Book Value ($M) | 160.41 |
| Book Value / Share | 17.09 |
| Price / Book | 0.79 |
| NCAV ($M) | 65.71 |
| NCAV / Share | 7.00 |
| Price / NCAV | 1.92 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.41 |
| Return on Assets (ROA) | -0.42 |
| Return on Equity (ROE) | -0.55 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.79 |
| Current Ratio | 8.79 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 131.53 |
| Assets | 226.24 |
| Liabilities | 65.83 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2.27 |
| Operating Income | -91.91 |
| Net Income | -83.58 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -60.07 |
| Cash from Investing | -123.35 |
| Cash from Financing | 69.36 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Citadel Advisors Llc | 3.90 | ||
| 13G | Driehaus Capital Management Llc | 5.28 | ||
| 13G | Alliancebernstein L.p. | 7.50 | ||
| 13G/A | Deep Track Capital, LP | 9.14 | 19.00 | |
| 13G/A | Cormorant Asset Management, LP | 2.86 | -49.77 | |
| 13G/A | Point72 Asset Management, L.P. | 7.80 | 32.99 | |
| 13G/A | Eventide Asset Management, Llc | 4.21 | -28.40 | |
| 13G/A | Fmr Llc | 6.23 | -20.30 | |
| 13G/A | Artal International S.C.A. | 4.50 | -1.32 | |
| 13D/A | New Enterprise Associates 17, L.P. | 11.80 | 1.66 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 22,030 | 71,915 | 30.63 | |
| 26,765 | 105,199 | 25.44 | |
| 16,783 | 72,284 | 23.22 | |
| 31,759 | 95,531 | 33.24 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| JSPR – Jasper Therapeutics, Inc. | KALA – KALA BIO, Inc. |
| KPRX – Kiora Pharmaceuticals, Inc. | KTTA – Pasithea Therapeutics Corp. |
| KZR – Kezar Life Sciences, Inc. |
Financial data and stock pages provided by
Fintel.io